158 วีระศักดิ์ นาวารวงศIX-V complex to lipid rafts is required for plateletadhesion and activation. J Exp Med 2002;196:1057-66.351. Takemoto M, Liao JK. Pleiotropic effects <strong>of</strong> 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.Arterioscler Thromb Vasc Biol 2001;21:1712-9.352. Liao JK. Isoprenoids as mediators <strong>of</strong> the biologicaleffects <strong>of</strong> statins. J Clin Invest 2002;110:285-8.353. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal<strong>of</strong> statins increases event rates in patients withacute coronary syndromes. Circulation 2002;105:1446-52.354. Rysanek R, Svelha S, Spankova H, Mlejnkova M. Theeffect <strong>of</strong> tricyclic antidepressive drugs on adrenalineand adenosine diphosphate induced plateletaggregation. J Pharmacol 1966;18:616.355. Warlow C, Ogston D, Douglas AS. <strong>Platelet</strong> functionafter administration <strong>of</strong> chlorpromazine to humansubjects. Haemostasis 1976;5:21356. Morishita S, Aoki S, Watanabe S. Different effect <strong>of</strong>desipramine on protein kinaseC in platelets betweenbipolar and major depressive disorders. PsychiatryClin Neurosci 1999;53:11.357. Blardi P, De Lalla A, Leo A, et al. Serotonin andfluoxetine levels in plasma and platelets afterfluoxetine treatment in depressive patients. J ClinPsychopharmacol 2002;22:131-6.358. Menys VC, Smith CC, Lewins P, et al. <strong>Platelet</strong> 5-hydroxytryptamine is decreased in a preliminarygroup <strong>of</strong> depressed patients receiving the 5-hydroxytryptaminere-uptake inhibiting drug fluoxetine.Clin Sci (Lond) 1996; 91:87-92.359. Alderman CP, Moritz CK, Ben Tovim DI. Abnormalplatelet aggregation associated with fluoxetinetherapy. Ann Pharmacother 1992;26:1517-9.360. Humphries JE, Wheby MS, VandenBerg SR.Fluoxetine and the bleeding time. Arch Pathol LabMed 1990;114:727-8.361. Pai VB, Kelly MW. Bruising associated with the use<strong>of</strong> fluoxetine. Ann Pharmacother 1996;30:786-8.362. Callahan KP, Malinin AI, Atar D, Serebruany VL.<strong>Platelet</strong> activation as a universal trigger in thepathogenesis <strong>of</strong> acute coronary events after cocaineabuse. Swiss Med Wkly 2001;131:487-9.363. Jennings LK, White MM, Sauer CM, et al. Cocaineinducedplatelet defects. Stroke 1993;24:1352-9.364. Pogliani EM, Fantasia R, Lambertenghi-Deliliers G,C<strong>of</strong>ranesco E. Daunorubicin and platelet function.Thromb Haemost 1981;45:38.365. McKenna R, Ahmad T, Ts’ao C-H, Frischer H.Glutathione reductase deficiency and plateletdysfunction induced by 1, 3-bis (2-chloroethyl)-1-nitrosourea. J Lab Clin Med 1983;102:102.366. Chlopicki S, Koda M, Chabielska E, et al. Antiplateletaction <strong>of</strong> losartan involves TXA 2receptorantagonismbut not TXA 2 synthase inhibition. J PhysiolPharmacol 2000;51:715-22.367. Langdell RD, Adelson E, Furth FW, Crosby WH.Dextran and prolonged bleeding time: Results <strong>of</strong> asixty-gram, one-liter infusion given to one hundredsixty-three normal human subjects. JAMA 1958;166:346-51.368. Aberg M, Hedner U, Bergentz S-E. Effect <strong>of</strong> dextran70 on factor VIII and platelet function in vonWillebrand’s disease. Thromb Res 1978;12:629.369. Weiss HJ. The effect <strong>of</strong> clinical dextran on plateletaggregation, adhesion, and ADP release in man: Invivo and in vitro studies. J Lab Clin Med 1967; 69:37-46.370. Mishler JM. Synthetic plasma volume expanders:Their pharmacology, safety and clinical efficacy. ClinHaematol 1984;13:75-92.371. Kelton JG, Hirsh J. Bleeding associated withantithrombotic therapy. Semin Hematol 1980;17:259.372. Korttila K, Lauritsalo K, S ärmö A. Suitability <strong>of</strong>plasma expanders in patients receiving low-doseheparin for prevention <strong>of</strong> venous thrombosis aftersurgery. Acta Anaesthesiol Scand 1983;27:104.373. Cope JT, Banks D, Mauney MC, et al. Intraoperativehetastarch infusion impairs hemostasis after cardiacoperations. Ann Thorac Surg 1997;63:78.374. Ruttmann TG, James MF, Aronson I. In vivoinvestigation into the effects <strong>of</strong> haemodilution withhydroxyethyl starch (200/0.5) and normal saline onThai Journal <strong>of</strong> Hematology and Transfusion Medicine Vol. 16 No. 2 April-June 2006
<strong>Acquired</strong> <strong>Disorders</strong> <strong>of</strong> <strong>Platelet</strong> <strong>Function</strong> (Part II)159coagulation. Br J Anaesth 1998;80:612.375. Roberts JS, Bratton SL. Colloid volume expanders:Problems, pitfalls and possibilities. Drugs 1998;55:621.376. Treib J, Haass A, Pindur G. Coagulation disorderscaused by hydroxyethyl starch. Thromb Haemost1997;78:974.377. Dyerberg J, Bang HO. Haemostatic function andplatelet polyunsaturated fatty acids in Eskimos.Lancet 1979;2:433-5.378. Kim DN, Eastman A, Baker JE, et al. Fish oil,atherogenesis, and thrombogenesis. Ann N Y AcadSci 1995;748:474-80.379. Schoene NW. Vitamin E and omega-3 fatty acids:Effectors<strong>of</strong>plateletresponsiveness. Nutrition 2001;17:793-6.380. Moncada S, Higgs EA. Arachidonate metabolism inblood cells and the vessel wall. Clin Haematol 1986;15:273.381. Leaf A, Weber PC. Cardiovascular effects <strong>of</strong> ω3 fattyacids. N Engl J Med 1988;318:549.382. Burr ML, Fehily AM, Gilbert JF, et al. Effects <strong>of</strong>changes in fat, fish, and fibre intakes on death andmyocardial reinfarction: Diet and reinfarction trial(DART). Lancet 1989;2:757-61.383. Dietary supplementation with ω-3 polyunsaturatedfatty acids and vitamin E after myocardial infarction:Results <strong>of</strong> the GISSI-Prevenzione trial. Gruppo Italianoper lo Studio della Sopravvivenza nell’Infarto miocardico.Lancet 1999;354:447-55.384. Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr.α-Tocopherol inhibits aggregation <strong>of</strong> human plateletsby a protein kinase C-dependent mechanism.Circulation 1996;94:2434-40.385. Deykin D, Janson P, McMahon L. Ethanolpotentiation <strong>of</strong> aspirin-induced prolongation <strong>of</strong> thebleeding time. N Engl J Med 1982;306:852-4.386. Hammerschmidt DE. Szechwan purpura. N Engl JMed 1980;302:1191-3.387. Rubin R. Effects <strong>of</strong> ethanol on platelets. Lab Invest.1990 ;63:729-32.388. Benistant C, Rubin R. Ethanol inhibits thrombininducedsecretion by human platelets at a sitedistinct from phospholipase C or protein kinase C.Biochem J 1990;269:489-97.วารสารโลหิตวิทยาและเวชศาสตรบริการโลหิต ปที่ 16 ฉบับที่ 2 เมษายน-มิถุนายน 2549